Pharmaceutical Technology Europe
The author lists five key areas to consider when selecting a CDMO to develop highly potent formulations.
Robert Harris
Advertisement
Articles by Robert Harris
The determination of topical bioequivalence requires a multi-faceted approach, tailored specifically to the generic-drug formulation.
Advertisement
Latest Updated Articles
Demonstrating Therapeutic Equivalence for Generic Topical ProductsNovember 2nd 2015
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pharma Fundamentals: Digital Pathology in Drug Development, Part 1
2
Risk-Based Life Cycle Management of Master Production and Control Records to Strengthen Data Integrity and GMP Inspection Readiness Part 2: Practical Considerations for CGMP Documentation Systems
3
EU Clears AstraZeneca's Trixeo for Asthma, Opening New Manufacturing Demand for Single-Inhaler Triple Therapy
4
PharmTech’s Weekly Roundup—September 25, 2026
5